All Updates

All Updates

icon
Filter
Funding
iOnctura raises EUR 80 million in Series B funding to develop uveal melanoma candidate
Precision Medicine
Jun 20, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 20, 2024

iOnctura raises EUR 80 million in Series B funding to develop uveal melanoma candidate

Funding

  • iOnctura has secured EUR 80 million (~USD 85.6 million) in a Series B funding round led by Syncona Limited, with participation from EIC Fund, M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. This brings the company's total funds to ~USD 128 million.

  • The secured funding will accelerate the development of iOnctura's lead candidate, roginolisib, to treat uveal melanoma (UM). The company claimed that in a Phase Ib clinical trial, roginolisib showed long-term safety and promising efficacy in treating UM, with sustained clinical activity observed over several months.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.